Fecal immunochemical test

Fecal immunochemical test has been studied in 49 papers since 2014: 3 trials and 21 observational studies in people, 16 reviews; 38 in the past year. The newest paper, Nov 5, 2026: “Diagnostic Accuracy and Colonoscopy-Sparing Potential of RAID-CRC Screen After a Positive Faecal Immunochemical Test”.

Intervention

49 papers study it19 findingsUpdated

3 new papers in 30 daysSee all 49 papers on fecal immunochemical test

At a glance

The findings reach people, from one lab or study. 8 independent labs in 5 countries; 10 trials, 1 about aging, 3 with no results posted.

“optimal cutoff increased sensitivity (14.3%-35.7%, P < 0.01)”
Accuracy of Fecal Immunochemical Tests for Detecting Advanced Colorectal Neoplasia at Surveillance ColonoscopyClinical and translational gastroenterology2026doi:10.14309/ctg.0000000000000997

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 8 independent labs in 5 countries
  • 10 trials, 1 about aging, 3 with no results posted
  • Funders: National Institutes of Health and others
  • Human trial3
  • Humans21
  • In silico9

Studies in people

1 study gave fecal immunochemical test to people and measured what changed.

What changedDesignPeopleSource

down: Lowers the risk of colorectal cancer

Randomized trialBoth50-69 yearsMidlife adults; Older adults; healthy adultsUnited European gastroenterology journal, Feb 20, 2026

What did studies of fecal immunochemical test find?

13

Studies of fecal immunochemical test measured 13 outcomes; the most studied is mortality (3 studies).

Mortality

downin humans2downin silico1

3 studies
  1. Fecal immunochemical test decreases mortality in colorectal cancer screening.

    “Fecal immunochemical testing (FIT) remains the cornerstone of organized, population-based colorectal cancer (CRC) screening owing to its noninvasive nature, affordability, and proven mortality reduction.”

    Reviewin colorectal cancer screening

    Best choice for colorectal cancer screening at the population level: fecal immunochemical test, stool DNA test, or colonoscopy

    Clinical endoscopy

  2. Fecal immunochemical test decreases mortality in humans (colorectal cancer).

    “The population-based screening programs in all three countries primarily utilize the fecal immunochemical test (FIT) and have demonstrably reduced CRC mortality.”

    Reviewcolorectal cancer

    Population Colorectal Cancer Screening in Asia: Insights From Established Programs

    Journal of gastroenterology and hepatology

  3. Fecal immunochemical test decreases mortality in silico (beginning at age 45 vs standard) (6100 fewer deaths).

    “screening at 45 would result in fewer CRC cases (15 070) and CRC deaths (6100) in Canada between 2025 and 2071.”

    In silicobeginning at age 45 vs standard

    Should we screen for colorectal cancer with biennial FIT beginning at age 45 in Canada?

    Journal of the Canadian Association of Gastroenterology

Modeled colonoscopy referrals

downin humans1

1 study
  1. Fecal immunochemical test is linked with lower modeled colonoscopy referrals in humans (Exploratory FIT118 threshold compared with FIT100) (149 colonoscopies avoided (11.5%); CRC sensitivity 100.0% (95% CI, 89.7–100.0%)).

    “FIT118 alone would avoid 149 colonoscopies (11.5%), with CRC sensitivity of 100.0% (95% CI, 89.7–100.0%)”

    HumansExploratory FIT118 threshold compared with FIT100n = 1,291

    Diagnostic Accuracy and Colonoscopy-Sparing Potential of RAID-CRC Screen After a Positive Faecal Immunochemical Test

    Diagnostics (Basel, Switzerland)

Sensitivity

upin humans1

1 study
  1. Fecal immunochemical test increases sensitivity in humans (for colorectal cancer vs advanced neoplasm detection) (78.6% vs. 32.3%).

    “FIT showed higher sensitivity for CRC than for AN (78.6% vs. 32.3%)”

    Reviewfor colorectal cancer vs advanced neoplasm detection

    Systematic Review and Meta-analysis of the Diagnostic Accuracy of Quantitative Fecal Immunochemical Tests by Sex, Geographic Region, and Test Characteristics

    Cancer research and treatment

Screening costs

downin silico1

1 study
  1. Fecal immunochemical test decreases screening costs in silico (annual screening episode in simulated 2021 cohort) (-94.5% ($22.4 billion savings)).

    “Replacing initial colonoscopy screening with FIT reduce total screening costs from US$23.7 billion to US$1.3 billion (94.5% reduction), saving US$22.4 billion.”

    In silicoannual screening episode in simulated 2021 cohort

    FIT and molecular tests versus colonoscopy: an economic evaluation of colorectal cancer screening in the United States

    Frontiers in oncology

Cost-effectiveness

upin silico1

1 study
  1. Fecal immunochemical test improves cost-effectiveness in silico (compared with TCS-based screening).

    “FIT-based screening was more cost-effective than TCS-based screening.”

    In silicocompared with TCS-based screening

    Cost-Effectiveness Analysis of Fecal Immunochemical Test-based Versus Total Colonoscopy-Based Colorectal Cancer Screening in Japan: A Microsimulation Study

    Value in health regional issues

Population health

upin silico1

1 study
  1. Fecal immunochemical test improves population health in silico (prioritising FITs over colonoscopies in the USA) (5.2 million disability-adjusted life-years per decade).

    “Prioritising FITs over colonoscopies in the USA could enhance population health by 5.2 million disability-adjusted life-years per decade.”

    In silicoprioritising FITs over colonoscopies in the USAper decade

    Comparative environmental impact analysis of screening tests for colorectal cancer: a single-centre life cycle assessment

    BMJ public health

Environmental impacts

downin silico1

1 study
  1. Fecal immunochemical test decreases environmental impacts in silico (roughly 20 percentage points superior to colonoscopies).

    “FITs had the lowest environmental impacts, roughly 20 percentage points superior to colonoscopies”

    In silico10 years

    Comparative environmental impact analysis of screening tests for colorectal cancer: a single-centre life cycle assessment

    BMJ public health

Colorectal cancer

downin silico1−25%

1 study
  1. Fecal immunochemical test decreases colorectal cancer in silico (simulated relative to no screening) (25%).

    “Relative to no screening, colonoscopy and FIT reduced late-stage diagnoses by 26% and 25%, respectively, versus 20%-32% for annual MCED screening.”

    In silicosimulated relative to no screening

    Should Multi-Cancer Early Detection Testing Replace Guideline-Recommended Colorectal Cancer Screening? A Comparative Modeling Analysis

    medRxiv : the preprint server for health sciencesPreprint

More on Colorectal cancer

Colorectal cancer mortality

downin humans1

1 study
  1. Fecal immunochemical test decreases colorectal cancer mortality in humans (asymptomatic, average-risk).

    “fecal immunochemical test (FIT) in reducing CRC mortality”

    Reviewasymptomatic, average-risk

    Korean Colorectal Cancer Screening Guidelines for Asymptomatic, Average-Risk Adults: The 2025 Revision

    Cancer research and treatment

Diagnostic specificity for advanced colorectal neoplasia

downin humans1

1 study
  1. Fecal immunochemical test decreases diagnostic specificity for advanced colorectal neoplasia in humans (previous nonadvanced lesions, comparing 26 ng/mL vs standard 100 ng/mL cutoff) (95.5%-79.2%, P < 0.01).

    “reduced specificity (95.5%-79.2%, P < 0.01)”

    Human trialprevious nonadvanced lesions, comparing 26 ng/mL vs standard 100 ng/mL cutoffstooln = 378

    Accuracy of Fecal Immunochemical Tests for Detecting Advanced Colorectal Neoplasia at Surveillance Colonoscopy

    Clinical and translational gastroenterology

Detection sensitivity for advanced colorectal neoplasia

upin humans1

1 study
  1. Fecal immunochemical test increases detection sensitivity for advanced colorectal neoplasia in humans (previous nonadvanced lesions, comparing 26 ng/mL vs standard 100 ng/mL cutoff) (14.3%-35.7%, P < 0.01).

    “optimal cutoff increased sensitivity (14.3%-35.7%, P < 0.01)”

    Human trialprevious nonadvanced lesions, comparing 26 ng/mL vs standard 100 ng/mL cutoffstooln = 378

    Accuracy of Fecal Immunochemical Tests for Detecting Advanced Colorectal Neoplasia at Surveillance Colonoscopy

    Clinical and translational gastroenterology

All 13

What is fecal immunochemical test linked with?

3

Studies link fecal immunochemical test with 3 measures: colorectal cancer, FIT concordance and Colonoscopy demand.

Colorectal cancer

downin humans1downin silico1

2 studies
  1. Fecal immunochemical test lowers the risk of colorectal cancer in humans (healthy adults).

    “The observed reductions in CRC-related mortality and CRC incidence, which were consistent across both screening strategies, were independent of sex or age.”

    Human trialhealthy adults

    Sex- and Age-Stratified Outcomes of Colonoscopy Versus Faecal Immunochemical Testing: Post-Analysis of the COLONPREV Study

    United European gastroenterology journal

  2. Fecal immunochemical test lowers the risk of colorectal cancer in silico (beginning at age 45 vs standard) (15 070 fewer cases).

    “Microsimulation results suggest that screening at 45 would result in fewer CRC cases (15 070) and CRC deaths (6100) in Canada between 2025 and 2071.”

    In silicobeginning at age 45 vs standard

    Should we screen for colorectal cancer with biennial FIT beginning at age 45 in Canada?

    Journal of the Canadian Association of Gastroenterology

More on Colorectal cancer

FIT concordance

no changein humans1

1 study
  1. Fecal immunochemical test is associated with FIT concordance in humans (residual stool samples tested by both at-home and in-laboratory FIT) (93% overall concordance).

    “A total of 1079 stool samples were tested using both at-home and in-laboratory FIT methods. Overall concordance was 93%.”

    Humansresidual stool samples tested by both at-home and in-laboratory FITstooln = 1,079

    Clinical Validation of a Simplified, Scrape-Free Collection Method for Multitarget Stool RNA Testing in Colorectal Cancer Screening

    Journal of clinical gastroenterology

More on FIT concordance

Colonoscopy demand

upin humans1

1 study
  1. Fecal immunochemical test predicts colonoscopy demand in humans (CRC screening among FONASA beneficiaries in Chile) (Estimated demand: 440,443 individuals).

    “The estimated colonoscopy demand corresponds to 440,443 individuals.”

    HumansCRC screening among FONASA beneficiaries in Chilesingle-sample qualitative53.71% womensn = 892

    Colonoscopy demand estimation for population-based colorectal cancer screening using fecal immunochemical test in Chile

    Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru

Has fecal immunochemical test been tested in people?

1 of 10 about aging

Yes: 3 trials and 21 observational studies in people have been published.

Funding

6 grants since 2016

National Cancer Institute$1MNational Institute for Health Research£406KJapan Society for the Promotion of Science¥4.8M

Contains public sector information licensed under the Open Government Licence v3.0.

Latest

Dec 2025: 2Jan 2026: 7Feb 2026: 6Mar 2026: 6Apr 2026: 0May 2026: 0Jun 2026: 3Jul 2026: 4Aug 2026: 4Sep 2026: 3Oct 2026: 2Nov 2026: 138 papers in 12 months

See all 49 papers on fecal immunochemical test